Treatments for locally advanced oropharyngeal cancer: A systematic review of clinical effectiveness and cost-effectiveness.

Abstract

The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH. CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites. Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governmentsor any third party supplier of information. This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

A Retrospective Review of Laser Therapy for Treatment of Hidradenitis Suppurativa

“…It works by reducing sweat secretion mediated by overactive cholinergic nerve fibers by blocking acetylcholine release and by reducing hyperhidrosis, causing a reduction of moist environments for bacterial proliferation and preventing the rupture and diffusion of follicular material through the dermis, which diminishes the promotion of inflammation and sinus tract formation 8,25–27 . Chemical cauterization with silver nitrate is used to treat open wounds to cauterize hemostasis after debridement and hypergranulation of tissue 28,29 . Finally, the Alexandrite laser was used to aid in follicular destruction 18 …”

“…8,[25][26][27] Chemical cauterization with silver nitrate is used to treat open wounds to cauterize hemostasis after debridement and hypergranulation of tissue. 28,29 Finally, the Alexandrite laser was used to aid in follicular destruction. 18 One limitation of this study was the assessment of patients' quality of life before and after treatment.…”

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder

“…RCTs of MOR-based MOUDs have been traditionally completed on an outpatient basis in settings, such as opioid treatment programs or medical offices, because of inherent restrictions on MOUD prescribing and dispensing. Some emerging treatments, such as sedative-hypnotics or vaccines, may have fewer regulatory or medical requirements compared with MOR-based treatments and therefore may afford more flexibility in the study designs and open opportunities for novel approaches . Methods for remote data collection have advanced considerably during the SARS-CoV-2 pandemic, expanding possible approaches to collecting substance use outcomes (eg, remotely collected breathalyzer data for alcohol or tobacco use) .…”

Experiences of Opioid Use Disorder Patients Receiving Buprenorphine Through a Telehealth Program

“…Given 81% of all Americans own a smart phone (Anderson, 2019), telehealth has become a very accessible alternative healthcare platform. In fact, research findings suggest higher retention rates among patients obtaining telehealth-delivered care when compared with standard in-person care (Ho & Argáez, 2018).…”

“…Although the clinical effectiveness of telehealth as a platform for treating patients with OUD is well established (Harris et al, 2020; Ho & Argáez, 2018; Uscher-Pines et al, 2020), little is known about patients' experience of telehealth, specifically while receiving buprenorphine treatment for OUD. Therefore, the purpose of this study was to explore the experiences of participants receiving MAT for OUD in a nurse practitioner (NP)-facilitated telehealth program.…”